Clinical study of Shenshi Qianghuo Dihuang Decoction in the treatment of Rheumatoid arthritis from the perspective of ''7+1''

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000003850

Enrollment

Unknown

Registered

2020-08-30

Start date

2020-10-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

experimental group:Qianghuo Dihuang Decoction + Methotrexate

control group:Methotrexate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria of rheumatoid arthritis, age 18-75 years old, male and female can be; The informed consent has been signed.

Exclusion criteria

Exclusion criteria: Having other diseases or drug contraindications; Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Dung conventional;Liver function;electrocardiogram;Blood sedimentation;Rheumatoid factor;Anti-cyclic citrullinate peptide antibody;Routine blood;renal function;Routine urine;	—

Countries

China

Contacts

Public ContactTang Huayan

Shanghai Traditional Chinese Medicine Hospital

18116013383@163.com+86 18116013383

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026